Dupilumab (Dupixent, Sanofi & Regeneron) Shows More Promise in BP
Dupilumab (Dupixent, Sanofi & Regeneron) hit all the key primary and secondary endpoints in a study of adults with Bullous Pemphigoid (BP). Results from the pivotal ADEPT Phase 2/3 trial were shared in a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, FL. In February 2025, the U.S. Food and Drug […]